CHST9 and triple-negative breast carcinoma: These enzymes play a pivotal role in tissue remodeling and are implicated in cancer development.[35,36] Polymorphisms in CHST9 significantly influence prognosis in early-stage triple-negative breast cancer, highlighting its clinical potential for identifying high-risk TNBC recurrence patients and guiding personalized treatment decisions.[37] Our in vitro functional experiments further confirmed that inhibiting CHST9 attenuates the proliferation, migration, and invasive capabilities of UVM cells, suggesting that CHST9 may serve as a potential therapeutic target for UVM.